• Je něco špatně v tomto záznamu ?

Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial

C. Herzog, A. Jones, I. Evans, D. Reisel, A. Olaitan, K. Doufekas, N. MacDonald, AF. Rådestad, K. Gemzell-Danielsson, M. Zikan, D. Cibula, L. Dostálek, T. Paprotka, A. Leimbach, M. Schmitt, A. Ryan, A. Gentry-Maharaj, S. Apostolidou, AN....

. 2024 ; 154 (4) : 679-691. [pub] 20231020

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000061

Grantová podpora
742432 European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme
N/A Land Tirol
The Eve Appeal

Analysis of cell-free DNA methylation (cfDNAme), alone or combined with CA125, could help to detect ovarian cancers earlier and may reduce mortality. We assessed cfDNAme in regions of ZNF154, C2CD4D and WNT6 via targeted bisulfite sequencing in diagnostic and early detection (preceding diagnosis) settings. Diagnostic samples were obtained via prospective blood collection in cell-free DNA tubes in a convenience series of patients with a pelvic mass. Early detection samples were matched case-control samples derived from the UK Familial Ovarian Cancer Screening Study (UKFOCSS). In the diagnostic set (ncases = 27, ncontrols = 41), the specificity of cfDNAme was 97.6% (95% CI: 87.1%-99.9%). High-risk cancers were detected with a sensitivity of 80% (56.3%-94.3%). Combination of cfDNAme and CA125 resulted in a sensitivity of 94.4% (72.7%-99.9%) for high-risk cancers. Despite technical issues in the early detection set (ncases = 29, ncontrols = 29), the specificity of cfDNAme was 100% (88.1%-100.0%). We detected 27.3% (6.0%-61.0%) of high-risk cases with relatively lower genomic DNA (gDNA) contamination. The sensitivity rose to 33.3% (7.5%-70.1%) in samples taken <1 year before diagnosis. We detected ovarian cancer in several patients up to 1 year before diagnosis despite technical limitations associated with archival samples (UKFOCSS). Combined cfDNAme and CA125 assessment may improve ovarian cancer screening in high-risk populations, but future large-scale prospective studies will be required to validate current findings.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000061
003      
CZ-PrNML
005      
20240213092940.0
007      
ta
008      
240109s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.34757 $2 doi
035    __
$a (PubMed)37861205
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Herzog, Chiara $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall in Tirol, Austria $u Research Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria $1 https://orcid.org/000000021572498X
245    10
$a Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial / $c C. Herzog, A. Jones, I. Evans, D. Reisel, A. Olaitan, K. Doufekas, N. MacDonald, AF. Rådestad, K. Gemzell-Danielsson, M. Zikan, D. Cibula, L. Dostálek, T. Paprotka, A. Leimbach, M. Schmitt, A. Ryan, A. Gentry-Maharaj, S. Apostolidou, AN. Rosenthal, U. Menon, M. Widschwendter
520    9_
$a Analysis of cell-free DNA methylation (cfDNAme), alone or combined with CA125, could help to detect ovarian cancers earlier and may reduce mortality. We assessed cfDNAme in regions of ZNF154, C2CD4D and WNT6 via targeted bisulfite sequencing in diagnostic and early detection (preceding diagnosis) settings. Diagnostic samples were obtained via prospective blood collection in cell-free DNA tubes in a convenience series of patients with a pelvic mass. Early detection samples were matched case-control samples derived from the UK Familial Ovarian Cancer Screening Study (UKFOCSS). In the diagnostic set (ncases = 27, ncontrols = 41), the specificity of cfDNAme was 97.6% (95% CI: 87.1%-99.9%). High-risk cancers were detected with a sensitivity of 80% (56.3%-94.3%). Combination of cfDNAme and CA125 resulted in a sensitivity of 94.4% (72.7%-99.9%) for high-risk cancers. Despite technical issues in the early detection set (ncases = 29, ncontrols = 29), the specificity of cfDNAme was 100% (88.1%-100.0%). We detected 27.3% (6.0%-61.0%) of high-risk cases with relatively lower genomic DNA (gDNA) contamination. The sensitivity rose to 33.3% (7.5%-70.1%) in samples taken <1 year before diagnosis. We detected ovarian cancer in several patients up to 1 year before diagnosis despite technical limitations associated with archival samples (UKFOCSS). Combined cfDNAme and CA125 assessment may improve ovarian cancer screening in high-risk populations, but future large-scale prospective studies will be required to validate current findings.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a prospektivní studie $7 D011446
650    12
$a metylace DNA $7 D019175
650    _2
$a časná detekce nádoru $x metody $7 D055088
650    12
$a nádory vaječníků $x diagnóza $x genetika $7 D010051
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a antigen CA-125 $7 D018394
650    _2
$a transkripční faktory Krüppel-like $x genetika $7 D051741
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jones, Allison $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
700    1_
$a Evans, Iona $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
700    1_
$a Reisel, Daniel $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
700    1_
$a Olaitan, Adeola $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
700    1_
$a Doufekas, Konstantinos $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
700    1_
$a MacDonald, Nicola $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
700    1_
$a Rådestad, Angelique Flöter $u Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Gemzell-Danielsson, Kristina $u Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Zikan, Michal $u Department of Gynecology and Obstetrics, Charles University in Prague, First Faculty of Medicine and Hospital, Na Bulovce, Czech Republic
700    1_
$a Cibula, David $u Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University, Prague and, General University Hospital, Prague, Czech Republic
700    1_
$a Dostálek, Lukáš $u Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University, Prague and, General University Hospital, Prague, Czech Republic
700    1_
$a Paprotka, Tobias $u GENEWIZ Germany GmbH, Bahnhofstraße, Germany
700    1_
$a Leimbach, Andreas $u Eurofins Genomics Europe Sequencing GmbH, Konstanz, Germany
700    1_
$a Schmitt, Markus $u Eurofins Genomics Europe Sequencing GmbH, Konstanz, Germany
700    1_
$a Ryan, Andy $u MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK
700    1_
$a Gentry-Maharaj, Aleksandra $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK $u MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK
700    1_
$a Apostolidou, Sophia $u MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK
700    1_
$a Rosenthal, Adam N $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
700    1_
$a Menon, Usha $u MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK $1 https://orcid.org/0000000337081732
700    1_
$a Widschwendter, Martin $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall in Tirol, Austria $u Research Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK $u Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden $1 https://orcid.org/0000000277788380
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 154, č. 4 (2024), s. 679-691
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37861205 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213092938 $b ABA008
999    __
$a ok $b bmc $g 2049019 $s 1209755
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 154 $c 4 $d 679-691 $e 20231020 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
GRA    __
$a 742432 $p European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme
GRA    __
$a N/A $p Land Tirol
GRA    __
$p The Eve Appeal
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace